Bosentan first-line treatment in pulmonary arterial hypertension: long-term clinical outcome and echocardiographic and Doppler measures

被引：0
|
作者：
Loban, C. Fernandez-Gofin [1 ]
Escribano, P. [1 ]
Tello, R. [1 ]
Gutierrez, H. [1 ]
Sanchez, M. A. Gomez [1 ]
Delgado, J. [1 ]
Jimenez, C. [1 ]
de la Calzada, C. Saenz [1 ]
机构：
[1] Hosp 12 Octubre, E-28041 Madrid, Spain
来源：
EUROPEAN HEART JOURNAL | 2005年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P588
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [41] Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
    Oudiz, Ronald J.
    Galie, Nazzareno
    Olschewski, Horst
    Torres, Fernando
    Frost, Adaani
    Ghofrani, Hossein A.
    Badesch, David B.
    McGoon, Michael D.
    McLaughlin, Vallerie V.
    Roecker, Ellen B.
    Harrison, Brooke C.
    Despain, Darrin
    Dufton, Christopher
    Rubin, Lewis J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (21) : 1971 - 1981
  • [42] Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence
    Provencher, S
    Sitbon, O
    Simonneau, G
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (08) : 1337 - 1348
  • [43] Combination therapy as first-line treatment of arterial hypertension
    Ruzicka, M
    Leenen, FHH
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2002, 18 (12) : 1317 - 1327
  • [44] Combined therapy as the first-line treatment for arterial hypertension
    Glezer, MG
    [J]. TERAPEVTICHESKII ARKHIV, 2005, 77 (10): : 93 - 96
  • [45] Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension
    Yanagisawa, Ryoji
    Kataoka, Masaharu
    Taguchi, Hiroki
    Kawakami, Takashi
    Tamura, Yuichi
    Fukuda, Keiichi
    Yoshino, Hideaki
    Satoh, Toni
    [J]. CIRCULATION JOURNAL, 2012, 76 (05) : 1245 - 1252
  • [46] Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?
    Clozel, M
    [J]. ANNALS OF MEDICINE, 2003, 35 (08) : 605 - 613
  • [47] Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension
    Zhao, Qin-Hua
    Peng, Fu-Hua
    Yu, Zai-Xin
    Zhang, Gang-Cheng
    Ji, Qiu-Shang
    Wang, Yong
    Liu, Jin-Ming
    Huo, Yong
    Zeng, Xiao-Feng
    Li, Jian-Hui
    Zi, Lu
    Jing, Zhi-Cheng
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2020, 18 (09) : 643 - 649
  • [48] Long-term outcomes in pulmonary arterial hypertension
    Thenappan, T.
    Palevsky, H. I.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 : 42 - 44
  • [49] Addition of Sildenafil to First Line Bosentan Therapy in Patients with Idiopathic Pulmonary Arterial Hypertension
    Savale, L.
    Sitbon, O.
    Le Pavec, J.
    Tcherakian, C.
    Jais, X.
    Achouh, L.
    Yaici, A.
    Humbert, M.
    Simonneau, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [50] Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
    Barst, R. J.
    Galie, N.
    Naeije, R.
    Simonneau, G.
    Jeffs, R.
    Arneson, C.
    Rubin, L. J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (06) : 1195 - 1203
12345